NCT06508268 · RECRUITING

Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease

This observational study is not testing a drug or treatment. Researchers are measuring how language, speech, and physical movement change across different stages of Alzheimer's — from MCI through mild and moderate disease — and comparing those results to healthy older adults. It is a data-collection effort, not a clinical trial in the traditional sense. There is no phase, no intervention being tested, and no experimental therapy involved.

Eligibility criteria

Inclusion Criteria:
A subject with MCI with a likelihood of underlying AD pathophysiology must meet the following criteria:
* Established diagnosis of MCI due to AD with a likelihood according to NIA-AA criteria (Albert et al., 2011).
* A score of stage three on the Global Deterioration Scale (GDS) (Reisberg et al., 1982).
A subject with AD must meet the following criteria:
* Established diagnosis of AD (amnestic or non-amnestic) or etiologically mixed presentation of AD according to DSM-5 (American Psychiatric Association, 2013) or NINCDS-ARDRA criteria (Jack et al., 2018; McKann et al., 2011).
* The following scores on the Global Deterioration Scale (GDS): four for mild AD, five for moderate AD (Reisberg et al., 1982).
All subjects of the control group must meet the following criteria:
* A score of stage one or two on the Global Deterioration Scale (GDS) (Reisberg et al., 1982).
* They are age-matched with the MCI due to AD or AD patients included in the study.
All subjects must meet the following criteria:
* First language is Dutch and/or Frisian.
* Able to walk independently with or without walking aid.
* Able to squeeze with each hand.
Exclusion Criteria:
A subject with MCI due to AD or AD who meets the following criteria will be excluded from participation in this study:
* Having a neurological or neurodegenerative disease or disorder that may be contributing to cognitive impairment above and beyond that caused by AD or mixed AD; Down's syndrome, other subtypes of dementia, autism spectrum disorder.
* Having an established diagnosis of a psychiatric disorder, e.g. schizophrenia, depression.
All subjects in the control group who meets following criteria will be excluded from participation in this study:
● Suffers from a neurological, neurodegenerative or psychiatric disease or disorder.
All subjects in any group who meet any of the following criteria will be excluded from participation in this study:
* Hearing loss (with or without hearing aid) that affects communication.
* Vision loss (with or without glasses or lenses) that affects communication.
* History of language problems, speech problems or dyslexia.
* Suffers from additional disorders or diseases which may limit gait, hand grip strength, language and/or speech.
* Medication use that influence gait, hand grip strength, speech or language performance at time of testing.
* Being terminally ill (i.e., life expectancy \< 2 weeks according to the attending physician).

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2024-07-18

View full record on ClinicalTrials.gov

All APOE4 clinical trials